Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 4:9:901990.
doi: 10.3389/fcvm.2022.901990. eCollection 2022.

Copeptin as a Diagnostic and Prognostic Biomarker in Cardiovascular Diseases

Danni Mu  1 , Jin Cheng  1 , Ling Qiu  1   2 , Xinqi Cheng  1
Affiliations
Review

Copeptin as a Diagnostic and Prognostic Biomarker in Cardiovascular Diseases

Danni Mu et al. Front Cardiovasc Med. .

Abstract

Copeptin is the carboxyl-terminus of the arginine vasopressin (AVP) precursor peptide. The main physiological functions of AVP are fluid and osmotic balance, cardiovascular homeostasis, and regulation of endocrine stress response. Copeptin, which is released in an equimolar mode with AVP from the neurohypophysis, has emerged as a stable and simple-to-measure surrogate marker of AVP and has displayed enormous potential in clinical practice. Cardiovascular disease (CVD) is currently recognized as a primary threat to the health of the population worldwide, and thus, rapid and effective approaches to identify individuals that are at high risk of, or have already developed CVD are required. Copeptin is a diagnostic and prognostic biomarker in CVD, including the rapid rule-out of acute myocardial infarction (AMI), mortality prediction in heart failure (HF), and stroke. This review summarizes and discusses the value of copeptin in the diagnosis, discrimination, and prognosis of CVD (AMI, HF, and stroke), as well as the caveats and prospects for the application of this potential biomarker.

Keywords: acute myocardial infarction; biomarker; cardiovascular diseases; copeptin; heart failure.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The structure, function, and clinical values of AVP and copeptin.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories 1980-2017: 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017 . Lancet. (2018) 392:1736–88. 10.1016/s0140-6736(18)32203-7 - DOI - PMC - PubMed
    1. Joseph P, Leong D, McKee M, Anand SS, Schwalm JD, Teo K, et al. . Reducing the global burden of cardiovascular disease, part 1: the epidemiology and risk factors. Circ Res. (2017) 121:677–94. 10.1161/CIRCRESAHA.117.308903 - DOI - PubMed
    1. Teo KK, Ounpuu S, Hawken S, Pandey MR, Valentin V, Hunt D, et al. . Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet. (2006) 368:647–58. 10.1016/S0140-6736(06)69249-0 - DOI - PubMed
    1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. (2002) 360:1903–13. 10.1016/S0140-6736(02)11911-8 - DOI - PubMed
    1. Wright JT, Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. . A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. (2015) 373:2103–16. 10.1056/NEJMoa1511939 - DOI - PMC - PubMed